marketcaparena
Search

    TRAW

    Traws Pharma, Inc.

    Company overview

    Market capitalization
    $8.90M
    Employees
    4
    Latest publication
    2026-09-29
    About Traws Pharma, Inc.

    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza. It is also developing narazaciclib, a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib, which is administered alone or in combination for investigation in various cancers. It has a license agreement with SymBio Pharmaceuticals Limited, Pint International SA, Viriom, Inc., Knight Therapeutics Inc., Specialised Therapeutics Asia Pte. Ltd., and Temple University. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue2,733,000USD57,000USD0USD0USD2,733,000USD57,000USD57,000USD57,000USD
    Research Development1,101,000USD4,912,000USD5,035,000USD2,311,000USD2,291,000USD2,505,000USD5,111,000USD5,111,000USD
    Total Operating Expenses3,175,000USD6,946,000USD7,368,000USD4,054,999USD3,982,000USD5,259,000USD8,591,000USD8,591,000USD
    Operating Income-1,405,000USD-6,946,000USD-7,368,000USD-4,054,999USD-1,249,000USD-5,203,000USD-8,536,000USD-8,536,000USD
    Gross Profit—57,000USD——2,733,000USD56,000USD55,000USD55,000USD
    Selling General Administrative—2,034,000USD2,333,000USD1,744,000,000USD1,691,000USD2,754,000USD3,480,000USD3,480,000USD
    Income Before Tax—-7,107,000USD-7,443,000USD-3,962,000USD-915,000USD21,490,000USD-8,475,000USD-8,475,000USD
    Net Income—-7,107,000USD-7,443,000USD-3,035,000USD-915,000USD15,083,000USD-8,475,000USD-8,475,000USD
    Net Income From Continuing Ops—-7,107,000USD-7,443,000USD-3,962,000USD-915,000USD21,490,000USD-29,922,000USD-8,475,000USD
    Ebit—-6,946,000USD——-1,249,000USD21,490,000USD-8,475,000USD-8,475,000USD
    Ebitda—-6,902,000USD—-3,962,000USD-1,248,000USD21,491,000USD-8,473,000USD-8,473,000USD
    Depreciation And Amortization—44,000USD——1,000USD1,000USD2,000USD2,000USD
    Reconciled Depreciation—44,000USD44,000USD15,000USD1,000USD1,000USD2,000USD2,000USD
    Total Other Income Expense Net—-161,000USD-75,000USD92,999USD334,000USD26,693,000USD61,000USD61,000USD
    Unclassified Operating Expenses———-1,742,256,001USD————
    Cost Of Revenue————1,000USD1,000USD2,000USD2,000USD
    SourceDisclosurePreliminaryLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue2,790,000USD226,000USD226,000USD226,000USD226,000USD231,000USD2,183,000USD1,228,000USD
    Cost Of Revenue61,000USD12,000USD16,000USD14,000USD14,000USD———
    Gross Profit2,790,000USD214,000USD226,000USD226,000USD226,000USD231,000USD2,183,000USD1,228,000USD
    Research Development12,143,000USD130,311,000USD11,430,000USD11,406,000USD7,297,000USD16,898,000USD15,537,000USD16,869,000USD
    Selling General Administrative8,522,000USD12,289,000USD9,094,000USD8,447,000USD9,425,000USD8,326,000USD8,345,000USD—
    Total Operating Expenses20,665,000USD49,562,000USD20,524,000USD19,853,000USD16,722,000USD25,224,000USD23,882,000USD24,455,000USD
    Operating Income-17,875,000USD-49,348,000USD-20,298,000USD-19,627,000USD-16,496,000USD-24,993,000USD-21,699,000USD-23,282,000USD
    Income Before Tax9,170,000USD-166,523,000USD-18,948,000USD-18,964,000USD-16,163,000USD-25,153,000USD-21,493,000USD-20,534,000USD
    Net Income9,170,000USD-54,674,000USD-18,948,000USD-18,964,000USD-16,163,000USD-25,157,000USD-21,503,000USD-20,573,000USD
    Net Income From Continuing Ops9,170,000USD-166,523,000USD-18,948,000USD-18,964,000USD-16,163,000USD-25,157,000USD——
    Ebit-17,875,000USD-166,523,000USD-20,298,000USD-19,627,000USD-16,496,000USD-24,993,000USD-21,699,000USD-20,534,000USD
    Ebitda-17,814,000USD-166,511,000USD-20,282,000USD-19,613,000USD-16,482,000USD-24,980,000USD-21,685,000USD-20,479,000USD
    Depreciation And Amortization61,000USD12,000USD16,000USD14,000USD14,000USD13,000USD14,000USD55,000USD
    Reconciled Depreciation61,000USD12,000USD16,000USD14,000USD14,000USD13,000USD——
    Total Other Income Expense Net27,045,000USD-117,175,000USD1,350,000USD663,000USD333,000USD-160,000USD206,000USD2,748,000USD
    Unclassified Operating Expenses—-93,038,000USD—————7,586,000USD
    Income Tax Expense——-151,895USD-214,485USD-321,000USD4,000USD10,000USD-124,000USD
    Tax Provision————0USD4,000USD10,000USD—
    Minority Interest——————0USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets11,470,000USD8,156,000USD10,617,000USD12,443,000USD15,622,000USD19,063,000USD24,962,000USD8,936,000USD
    Total Current Assets9,023,000USD5,665,000USD7,979,000USD9,625,000USD15,370,000USD18,856,000USD24,951,000USD8,923,000USD
    Other Current Assets93,000USD845,000USD89,000USD1,214,000USD966,000USD1,265,000USD1,848,000USD1,392,000USD
    Other Non Current Assets1,000USD———————
    Total Liabilities9,779,000USD———————
    Total Current Liabilities9,735,000USD13,208,000USD11,146,000USD7,887,000USD7,352,000USD10,401,000USD11,533,000USD8,348,000USD
    Other Current Liabilities3,401,000USD———————
    Total Equity Including Noncontrolling Interest1,691,000USD———————
    Property Plant Equipment Net5,000USD6,000USD7,000USD7,000USD8,000USD9,000USD10,000USD12,000USD
    Accounts Payable6,334,000USD7,665,000USD5,653,000USD5,105,000USD4,759,000USD7,656,000USD8,186,000USD5,472,000USD
    Common Stock152,000USD101,000USD—71,000USD71,000USD50,000USD36,000USD30,000USD
    Retained Earnings-650,145,000USD-647,091,000USD-639,984,000USD-632,541,000USD-628,579,000USD-627,664,000USD-649,154,000USD-619,232,000USD
    Accumulated Other Comprehensive Income-5,000USD-2,000USD—6,000USD9,000USD-19,000USD-42,000USD-33,000USD
    Intangible Assets—2,484,000USD2,527,000USD2,571,000USD————
    Total Liab—13,467,000USD11,246,000USD7,898,000USD7,360,000USD13,063,000USD56,592,000USD10,969,000USD
    Total Stockholder Equity—-5,311,000USD-629,000USD4,545,000USD8,262,000USD6,000,000USD-31,630,000USD-2,033,000USD
    Other Current Liab—5,543,000USD128,000USD2,782,000USD2,593,000USD2,519,000USD3,121,000USD2,650,000USD
    Capital Stock—101,000USD90,000USD71,000USD71,000USD50,000USD36,000USD30,000USD
    Cash—3,133,000USD3,820,000USD6,420,000USD13,081,000USD15,937,000USD21,338,000USD5,410,000USD
    Cash And Short Term Investments—3,133,000USD—6,420,000USD13,081,000USD15,937,000USD21,338,000USD5,410,000USD
    Net Debt—-3,133,000USD—-6,420,000USD-13,081,000USD-15,937,000USD-21,338,000USD-5,410,000USD
    Net Receivables—1,687,000USD3,794,000USD1,991,000USD1,323,000USD1,654,000USD1,765,000USD2,121,000USD
    Common Stock Shares Outstanding—10,640,625shares9,067,774shares8,819,000shares5,820,903shares7,215,125shares961,530shares961,530shares
    Non Current Assets Total—2,491,000USD2,638,000USD2,817,999USD252,000USD207,000USD11,000USD13,000USD
    Non Current Liabilities Total—259,000USD100,000USD11,000USD8,000USD2,662,000USD45,059,000USD2,621,000USD
    Non Currrent Assets Other—1,000USD104,000USD239,999USD244,000USD198,000USD1,000USD1,000USD
    Net Working Capital—-7,543,000USD-3,167,000USD1,738,000USD8,018,000USD8,455,000USD13,418,000USD575,000USD
    Unclassified Equity—641,580,000USD639,265,000USD636,938,000USD636,690,000USD633,583,000USD617,494,000USD617,172,000USD
    Property Plant Equipment Gross——84,000USD84,000USD84,000USD84,000USD84,000USD84,000USD
    Unclassified Current Liabilities——5,365,000USD—————
    Current Deferred Revenue—————226,000USD226,000USD226,000USD
    Unclassified Non Current Liabilities—————2,662,000USD45,059,000USD2,621,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets10,617,000USD24,962,000USD22,683,000USD39,372,000USD55,478,000USD19,986,000USD23,674,000USD17,923,000USD
    Intangible Assets2,527,000USD———————
    Other Current Assets365,000USD1,848,000USD1,821,000USD561,000USD332,000USD180,000USD650,000USD760,000USD
    Total Liab11,246,000USD56,592,000USD12,011,000USD11,063,000USD9,358,000USD13,811,000USD12,100,000USD12,536,000USD
    Total Stockholder Equity-629,000USD-31,630,000USD10,672,000USD28,309,000USD46,120,000USD6,175,000USD11,574,000USD5,387,000USD
    Other Current Liab5,493,000USD3,121,000USD3,375,000USD3,960,000USD3,132,000USD4,962,000USD3,795,000USD4,173,000USD
    Common Stock90,000USD36,000USD210,000USD209,000USD209,000USD124,000USD1,112,000USD57,000USD
    Capital Stock90,000USD36,000USD210,000USD209,000USD209,000USD124,000USD——
    Retained Earnings-639,984,000USD-649,154,000USD-482,631,000USD-463,683,000USD-444,719,000USD-428,556,000USD-403,399,000USD-381,896,000USD
    Cash3,820,000USD21,338,000USD20,821,000USD38,757,000USD55,070,000USD19,025,000USD22,726,000USD16,970,000USD
    Cash And Short Term Investments3,820,000USD21,338,000USD20,821,000USD38,757,000USD55,070,000USD19,025,000USD22,726,000USD16,970,000USD
    Total Current Assets7,979,000USD24,951,000USD22,660,000USD39,347,000USD55,430,000USD19,784,000USD23,474,000USD17,765,000USD
    Total Current Liabilities11,146,000USD11,533,000USD9,220,000USD8,046,000USD6,115,000USD10,021,000USD8,292,000USD8,438,000USD
    Net Debt-3,820,000USD-21,338,000USD-20,821,000USD-38,757,000USD-55,070,000USD-19,025,000USD-22,726,000USD-16,970,000USD
    Net Receivables3,794,000USD1,765,000USD18,000USD29,000USD28,000USD37,000USD98,000USD35,000USD
    Accounts Payable5,653,000USD8,186,000USD5,619,000USD3,860,000USD2,757,000USD4,833,000USD4,271,000USD4,039,000USD
    Property Plant Equipment Net7,000USD10,000USD22,000USD24,000USD38,000USD52,000USD50,000USD9,000USD
    Property Plant Equipment Gross84,000USD84,000USD84,000USD70,000USD70,000USD70,000USD——
    Accumulated Other Comprehensive Income6,000USD-42,000USD-23,000USD-33,000USD-14,000USD14,000USD-18,000USD-12,000USD
    Common Stock Shares Outstanding8,376,380shares1,552,685shares839,554shares836,329shares673,287shares464,095shares38,358shares10,997shares
    Non Current Assets Total2,638,000USD11,000USD23,000USD25,000USD48,000USD202,000USD200,000USD158,000USD
    Non Current Liabilities Total100,000USD45,059,000USD2,791,000USD3,017,000USD3,243,000USD3,790,000USD3,808,000USD4,098,000USD
    Non Currrent Assets Other104,000USD1,000USD1,000USD1,000USD10,000USD150,000USD150,000USD149,000USD
    Net Working Capital-3,167,000USD13,418,000USD13,440,000USD31,301,000USD49,315,000USD9,763,000USD——
    Unclassified Equity639,169,000USD617,494,000USD492,906,000USD491,607,000USD490,435,000USD434,469,000USD413,879,000USD387,238,000USD
    Current Deferred Revenue—226,000USD226,000USD226,000USD226,000USD226,000USD226,000USD226,000USD
    Unclassified Non Current Liabilities—45,059,000USD2,791,000USD3,017,000USD3,243,000USD3,790,000USD3,808,000USD4,098,000USD
    Inventory——1,420,000USD521,000USD297,000USD542,000USD——
    Unclassified Current Assets——-1,420,000USD—————
    Other Assets——————1USD1USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation88,000USD
    Stock Based Compensation1,450,000USD
    Change To Liabilities534,000USD
    Change In Working Capital351,000USD
    Operating Cash Flow-10,080,000USD
    Financing Cash Flow11,287,000USD
    Effect Of Forex Changes On Cash-11,000USD
    Change In Cash1,196,000USD
    End Cash Flow5,016,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-7,107,000USD-5,398,000USD-3,035,000USD-625,000USD21,490,000USD81,927,000USD-8,475,000USD-123,143,000USD
    Depreciation44,000,000USD44,000USD15,000USD1,000USD1,000USD2,000USD2,000USD4,000USD
    Stock Based Compensation634,000,000USD327,000USD135,000USD105,000USD161,000USD677,000USD343,000USD713,000USD
    Other Non Cash Items-677,163,000USD—-789,000USD-331,000USD-26,513,000USD-87,077,000USD0USD117,844,000USD
    Change To Account Receivables2,107,000USD—-668,000USD331,000USD111,000USD356,000USD-2,103,000USD—
    Change In Working Capital3,694,000USD4,225,000USD-202,000USD-5,024,000USD-576,000USD1,108,000USD-3,346,000USD-4,557,000USD
    Total Cash From Operating Activities-2,576,000USD-2,758,000USD-4,011,000USD-5,979,000USD-5,437,000USD-4,040,000USD-11,476,000USD-9,852,000USD
    Capital Expenditures-2,585,000USD0USD0USD0USD0USD0USD0USD0USD
    Free Cash Flow-2,576,000,000USD-2,758,000USD-4,011,000USD-5,979,000USD-5,437,000USD-4,040,000USD-11,476,000USD-9,852,000USD
    Total Cashflows From Investing Activities-2,585,000USD—-2,585,000USD————-3,648,000USD
    Total Cash From Financing Activities1,897,000USD158,000USD-62,000USD3,095,000USD13,000USD19,977,000USD0USD13,999,000USD
    Sale Purchase Of Stock-2,404,000USD———————
    Issuance Of Capital Stock1,897,000USD2,087,000USD116,000USD3,257,000USD122,000USD19,977,000USD0USD13,999,000USD
    Change In Cash-687,000USD-2,600,000USD-6,661,000USD-2,856,000USD-5,401,000USD15,928,000USD-11,476,000USD496,000USD
    Begin Period Cash Flow3,820,000,000USD6,420,000USD13,081,000USD15,937,000USD21,338,000USD5,410,000USD16,886,000USD16,390,000USD
    End Period Cash Flow3,133,000,000USD3,820,000USD6,420,000USD13,081,000USD15,937,000USD21,338,000USD5,410,000USD16,886,000USD
    Other Cashflows From Financing Activities-1,939,000USD——-3,419,000USD-109,000USD——-3,648,000USD
    Unclassified Financing Cash Flow6,240,000USD-1,929,000USD—3,257,000USD———3,648,000USD
    Unclassified Operating Cash Flow—-1,956,000USD——————
    Investments——-2,585,000USD——0USD0USD—
    Other Cashflows From Investing Activities—————3,647,996,352,000USD——
    Unclassified Investing Cash Flow———————-3,648,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income9,170,000USD-54,674,000USD-18,948,000USD-18,964,000USD-16,163,000USD-25,157,000USD-21,503,000USD-20,573,000USD
    Depreciation61,000USD12,000USD16,000USD14,000USD14,000USD13,000USD14,000USD55,000USD
    Stock Based Compensation728,000USD1,390,000USD1,301,000USD1,172,000USD576,000USD369,000USD——
    Other Non Cash Items-26,115,000USD31,443,000USD1,301,000USD1,172,000USD-321,000USD577,000USD985,000USD-1,111,000USD
    Change To Account Receivables-2,029,000USD-1,747,000USD11,000USD-1,000USD9,000USD61,000USD-63,000USD24,000USD
    Change In Working Capital-2,029,000USD-6,573,000USD-301,000USD1,484,000USD-3,593,000USD1,492,000USD-327,000USD-1,067,000USD
    Total Cash From Operating Activities-18,185,000USD-29,792,000USD-17,932,000USD-16,294,000USD-19,487,000USD-23,075,000USD-20,831,000USD-22,696,000USD
    Capital Expenditures-2,585,000USD0USD-14,000USD0USD0USD-15,000USD-55,000USD0USD
    Free Cash Flow-20,770,000USD-29,792,000USD-17,946,000USD-16,294,000USD-19,487,000USD-23,090,000USD-20,886,000USD-22,696,000USD
    Total Cashflows From Investing Activities-2,585,000USD-3,648,000USD-14,000USD——-15,000USD-55,000USD—
    Total Cash From Financing Activities3,204,000USD33,976,000USD0USD0USD55,560,000USD19,357,000USD26,648,000USD35,657,000USD
    Sale Purchase Of Stock-2,404,000USD———————
    Issuance Of Capital Stock5,582,000USD33,976,000USD0USD0USD55,041,000USD9,062,000USD21,759,000USD—
    Change In Cash-17,518,000USD517,000USD-17,936,000USD-16,313,000USD36,045,000USD-3,701,000USD5,756,000USD12,946,000USD
    Begin Period Cash Flow21,338,000USD20,821,000USD38,757,000USD55,070,000USD19,025,000USD22,726,000USD16,970,000USD4,024,000USD
    End Period Cash Flow3,820,000USD21,338,000USD20,821,000USD38,757,000USD55,070,000USD19,025,000USD22,726,000USD16,970,000USD
    Other Cashflows From Investing Activities-2,585,000,000USD———————
    Other Cashflows From Financing Activities3,204,000,000USD—-14,000USD—519,000USD10,295,000USD4,889,000USD589,000USD
    Unclassified Investing Cash Flow2,585,000,000USD———————
    Unclassified Financing Cash Flow-3,198,392,000USD——————35,068,000USD
    Investments—-3,648,000USD-14,000USD0USD0USD-15,000USD——
    Unclassified Operating Cash Flow—-1,390,000USD-1,301,000USD-1,172,000USD————
    Change To Inventory——-11,000USD1,000USD-9,000USD-61,000USD——
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2020Quarterly · 2020-09-30ProductLicense56,000USD0001558370-21-016043
    Q3 2020Quarterly · 2020-09-30ProductSupplies And Other10,000USD0001558370-21-016043
    Q1 2020Quarterly · 2020-03-31ProductLicense56,000USD0001104659-21-068301
    Q1 2020Quarterly · 2020-03-31ProductSupplies And Other-4,000USD0001104659-21-068301
    FY 2019Yearly · 2019-12-31ProductOther377,000USD0001104659-21-038452
    FY 2019Yearly · 2019-12-31ProductRigosertib1,751,000USD0001104659-21-038452
    FY 2019Yearly · 2019-12-31ProductSupplies55,000USD0001104659-21-038452
    Q3 2019Quarterly · 2019-09-30ProductLicense57,000USD0001104659-20-125819
    Q3 2019Quarterly · 2019-09-30ProductSupplies And Other6,000USD0001104659-20-125819
    Q2 2019Quarterly · 2019-06-30ProductHanx Upfront License Payment1,965,000USD0001104659-19-045963
    Q2 2019Quarterly · 2019-06-30ProductSymbio Amortization Of Upfront Payment56,000USD0001104659-19-045963
    Q2 2019Quarterly · 2019-06-30ProductSymbio Clinical Supplies1,000USD0001104659-19-045963
    Q1 2019Quarterly · 2019-03-31ProductSupplies And Other11,000USD0001104659-20-062608
    Q1 2019Quarterly · 2019-03-31ProductUpfront License Fee Recognition Over Time57,000USD0001104659-20-062608
    FY 2018Yearly · 2018-12-31ProductHanx Upfront Licence Payment450,000USD0001047469-19-001839
    FY 2018Yearly · 2018-12-31ProductPint Upfront Licence Payment319,000USD0001047469-19-001839
    FY 2018Yearly · 2018-12-31ProductSupplies61,000USD0001047469-19-001839
    FY 2018Yearly · 2018-12-31ProductSymbio Amortization Of Upfront Payment398,000USD0001047469-19-001839
    Q3 2018Quarterly · 2018-09-30ProductSymbio Amortization Of Upfront Payment114,000USD0001104659-18-068490
    Q3 2018Quarterly · 2018-09-30ProductSymbio Clinical Supplies6,000USD0001104659-18-068490
    Q2 2018Quarterly · 2018-06-30ProductPint Upfront License Payment319,000USD0001104659-19-045963
    Q2 2018Quarterly · 2018-06-30ProductSymbio Amortization Of Upfront Payment113,000USD0001104659-19-045963
    Q2 2018Quarterly · 2018-06-30ProductSymbio Clinical Supplies53,000USD0001104659-19-045963
    FY 2017Yearly · 2017-12-31ProductSupplies332,000USD0001047469-19-001839
    FY 2017Yearly · 2017-12-31ProductSymbio Amortization Of Upfront Payment455,000USD0001047469-19-001839
    Q2 2017Quarterly · 2017-06-30ProductSymbio Amortization Of Upfront Payment113,000USD0001104659-18-052015
    Q2 2017Quarterly · 2017-06-30ProductSymbio Clinical Supplies211,000USD0001104659-18-052015

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.